CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers

CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers

CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers

CytoSMART to donate 100 live-cell imaging systems to assist COVID-19 researchers

Eindhoven, The Netherlands – 22 April 2020, – CytoSMART Technologies is to donate 100 mini live-cell imaging systems to researchers in high containment labs worldwide. Labs working to combat COVID-19 will benefit from this initiative, as CytoSMART aims to reduce the huge workload currently facing researchers on projects vital to controlling the disease.

“We aim to do our part to assist researchers in minimizing the time they have to spend in high-contamination labs, by providing them with remote video access to evaluate the status of their cell cultures. The video data is used to remotely monitor the cytopathic effect, this way researchers know when it’s the right time to harvest the virus.” – Joffry Maltha, CEO at CytoSMART Technologies

Laboratories are welcome to apply for a CytoSMART Lux2 live-cell imager here.
According to guidelines by the CDC and the WHO, isolation and characterization of COVID-19 should be performed in BSL-3 laboratories. Performing research in Biosafety Level 3 and 4 laboratories (BSL-3 or BSL-4) means working in a highly controlled area. Many precautionary measures must be taken to ensure the safety of researchers and help prevent the diseases they are working with from spreading outside the lab. Removing and replacing the protective clothing and apparatus can be time consuming and expensive, so entering the lab should ideally only occur when absolutely necessary.

CytoSMART’s unique and compact live-cell microscope films living cell cultures without disturbing their growth or behaviour. The device operates from inside cell culture incubators and is accessible from an online environment. This enables researchers to analyse their cell cultures remotely and assess e.g. the cytopathic effect, which is caused by virus replication. Using the CytoSMART Lux2, researchers will know when to take action for the next step and harvest the virus.

Said Maltha,“We need to help scientists who are working in BSL-3 and BSL-4 laboratories to combat COVID-19. We know that our system can help researchers in monitoring cell growth and deciding when they need to go to the high containment labs and run further experiments.

The work of such labs is absolutely essential in the fight against COVID-19 and it’s important to us as an organisation to help where we can. This useful tool can support them in their hard work, by helping to save precious time and equipment by knowing exactly when to enter the lab.

Please forward this message to anyone in your network, working in a lab helping the world to find a cure against this disease.”

About CytoSMART:

CytoSMART Technologies is a company that develops and manufactures smart microscope systems for life science labs. The company was founded in 2012 by a team of biologists and engineers. They were convinced that a new generation of miniaturized microscopes, powered by artificial intelligence for image analysis, would allow biologists to make discoveries more quickly and in a reproducible manner. In 2018 CytoSMART was selected by Microsoft for their prestigious Scale Up program. CytoSMART’s microscopy solutions are used in over a thousand laboratories around the world.

 

Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR

Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR

Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR

Yenlo Achieves Highest WSO2 Reseller Status as a Platinum VAR

Yenlo was named a WSO2 Platinum Value-Added Reseller in recognition of its success in growing global customer adoption and delivering best-in-class open source integration and API management solutions based on the WSO2 platform.

Amsterdam, The Netherlands, 16 April 2020. Global integration specialist Yenlo today announced that the company is now a WSO2 Platinum Value-Added Reseller, the highest reseller status recognized by WSO2, the leading open source integration vendor. Yenlo is the only Platinum VAR of WSO2 acting and delivering on a global, worldwide level.

WSO2 VARs must meet the same stringent certification requirements demanded of WSO2 Certified Integration Partners. Yenlo’s new designation builds on the company’s multi-year partnership with WSO2, and it recognizes Yenlo’s strong history of successful projects, subscription sales, and extensive WSO2-certified engineering staff. In January 2020, Yenlo earned two awards from WSO2: Partner of the Year 2019 awarded Yenlo for its overall performance. Meanwhile, Most Certified Partner of 2019 recognized Yenlo’s achievement in assembling the largest talent pool of WSO2-certified staff in the world.

Yenlo brings 12-plus years of expertise in delivering solutions for enterprise applications, middleware, and database platforms for traditional servers, private clouds, and public clouds. As a WSO2 Platinum VAR with all the responsibilities of a Certified Integration Partner, Yenlo delivers integration, API management, and identity and access management (IAM) solutions based on the WSO2 Integration Agile Platform that enable agile digital transformation and support organizations’ API-first strategies.

In 2019, Yenlo extended its delivery of WSO2-based solutions with the introduction of the Connext integration platform as a service (iPaaS), a fully managed integration WSO2 cloud platform built on Amazon Web Services (AWS). Notably, Connext is the solution of choice for banks that need to comply with open banking API standards and enterprises seeking a cloud platform that brings together API management, integration for both traditional applications and microservices, and IAM to streamline their deployments. With local offices across North America, Europe and Asia-Pacific, Yenlo is well positioned to serve customers around the globe 24/7 in maximizing the value from their WSO2-powered implementations.

“Yenlo has been a valued, strategic partner for years, and we are excited to recognize the company as a Platinum Value-Added Reseller based on its success in delivering best-in-class solutions built on the WSO2 Agile platform,” said Jonathan Marsh, WSO2 vice president of strategy. “Yenlo shares our vision of enabling digital businesses through API-first strategies, and we look forward to extending our partnership as Yenlo continues to drive successful customer deployments of our platform across North America, Europe and Asia.”

“As a dedicated WSO2 Partner, we work on the global adoption of WSO2 on a daily basis, so we are greatly honored to be recognized as a WSO2 Platinum Value-Added Reseller,” Ruben van der Zwan, CEO and co-founder of Yenlo. “Earning WSO2’s highest reseller recognition is a testament to our commitment, skill, and large customer base. In this new role, we are better positioned than ever to accelerate global adoption of WSO2 by demonstrating to every enterprise the power of this open source integration solution.”

About WSO2
Founded in 2005, WSO2 enables the composable enterprise. Our open source, API-first, and decentralized approach helps developers and architects to be more productive and rapidly build digital products to meet demand. Customers choose us for our broad, integrated platform, approach to open source, and digital transformation methodology. The company’s hybrid platform for developing, reusing, running, and managing integrations prevents lock-in through open source software that runs on-premises or in the cloud. With offices in Australia, Brazil, Germany, Sri Lanka, the UK, and the US, WSO2 employs over 600 engineers, consultants, and professionals worldwide. Today, hundreds of leading brands and thousands of global projects execute over 6 trillion transactions annually using WSO2 integration technologies. Visit https://wso2.com to learn more. Follow WSO2 on LinkedIn and Twitter.

About Yenlo
Yenlo is a global integrator and specialist in enabling digital transformation with open source and agile technology. Yenlo is a Platinum Value-Added Reseller (VAR) of WSO2 and has been awarded both WSO2 Partner of the Year 2018 and 2019 and WSO2 Most Certified Partner of 2019. Our business is founded on the belief that enterprises need to regain their agility and become digital agencies to optimize their customer intimacy; achieve operational excellence; or add new services, products, or business models. We believe this agility—in technology, knowledge and finance—can be created by applying an open source-first, API-first, and cloud-first strategy.

At Yenlo, we bring agility to enterprises by delivering first-class professional services based on deep expertise. Our services range from enterprise and solution architecture to software development; operational support; and WSO2 product support, training and certification programs. These are complemented by our pre-built solution-as-a-service offerings, including our Connext service, a fully managed integration-platform-as-a-service. For more information, visit www.yenlo.com, and join Yenlo’s LinkedIn, Yenlo’s WSO2 Community, or Twitter.

Trademarks and registered trademarks are the properties of their respective owners.

Portfolio company Inno4Life sold to the Swiss company Dec Group

Portfolio company Inno4Life sold to the Swiss company Dec Group

Portfolio company Inno4Life sold to the Swiss company Dec Group

Portfolio company Inno4Life sold to the Swiss company Dec Group

Amsterdam, April 16, 2020 – Earlier this month, Inno4Life, a manufacturer of machines for the pharmaceutical industry, was sold to the Swiss Dec Group. Inno4Life’s management will remain actively involved in the company after its acquisition, which will continue to operate under its own name.

Inno4Life is an innovative manufacturer of complex filling and packaging machines for the pharmaceutical industry. The company distinguishes itself through its extensive knowledge and experience and the delivery of tailor-made solutions to its customers. Its customers include leading pharmaceutical companies.

International growth ambitions
To enable further international growth, Inno4Life has searched for a strong partner and found this partner in Dec Group.

Johan Klootwijk, co-founder and Managing Director of Inno4Life, commented: “Dec’s acquisition provides a major growth opportunity for both our businesses through an enhanced service offering for our clients. We will be best positioned to offer outstanding quality solutions and increased effectiveness as a result of combined action and co-operation.”

Jan-Frens van Giessel, healthcare partner at Holland Capital, is also pleased with the acquisition: “Inno4Life has gained a strong position within the pharmaceutical industry. The acquisition by Dec is a logical next step, that enables Inno4Life continuing their international expansion. We wish Inno4Life and Dec a successful joint future.”

About Holland Capital
Over the past 38 years, Holland Capital has invested successfully in over 140 small and medium-sized enterprises in the Netherlands. With a clear investment strategy, it focuses its activities in the attractive growth markets of Healthcare and Tech. Holland Capital’s experienced and dedicated investment team knows what doing business means. They strive for an open, long-term and professional relationship with the management teams of the enterprises Holland Capital invests in, with the shared goal of achieving growth. Holland Capital is supported by a broad network of successful businesses in Healthcare and Tech.

About Dec
Dec is a leading global provider of contained powder handling systems and is recognized as a world-leading expert in process containment technologies. It has been supplying the pharmaceutical, chemical, food and cosmetic industries for more than 30 years. Headquartered in Switzerland, Dec has a global presence in more than 30 countries. In excess of 600 companies worldwide have successfully integrated more than 9000 Dec systems into their production sites. These include a wide range of patented products that enhance safety, hygiene, containment, reliability and productivity in powder handling.

Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven

Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven

Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven

Dutch Ministry of Health also opts for Evone® by Ventinova from Eindhoven
Results of FCV®-equipped ventilation equipment appears promising

Eindhoven, 2 April 2020 – Ventinova Medical, a company based in Eindhoven, received good news today; this concerns a substantial order for the delivery of Evone®, an innovative ventilation device, equipped with the FCV® technology patented by Ventinova, which controls both the supply and the exhaust of air during mechanical ventilation. This is a global first.

New technology
The guiding principle for the design of Evone® was to develop a device that is as effective as possible and that prioritises the health and recovery of the patients. The company worked on this aspect for many years. Evone® is based on Ventinova’s FCV® ventilation technology. The significant clinical benefits of FCV® have been demonstrated in several international clinical trials in recent years. Simply put, this device results in a strongly improved oxygen transfer, because the lungs remain open more effectively during the so-called expiratory phase (‘exhalation phase’). This minimises lung damage as a result of ventilation and allows for a faster recovery. Evone® can be life-saving, particularly for patients in a critical condition.

Superior ventilation
Ventinova CEO Dirk van Asseldonk: ‘The market for ventilation equipment is incredibly dynamic at the moment. It is important not to lose sight of the crux of this application; at the moment, the crux is the ventilation of corona patients in ICUs, in critical condition. Due to the specific mechanism of the patented FCV® technology, Evone® allows us to offer superior ventilation for patients.

We need to remain cautions about the conclusions, but initial experiences gained in the ventilation of Covid-19 patients appear to confirm that these patients recover more quickly than with conventional ventilation

Just last night we received a report of a very impressive case: the patient was initially so ill that he normally would not even be able to receive ventilation and instead he would have required a cardiopulmonary bypass machine. This patient was able to come off the ventilator after just over six days of ventilation with Evone®!

An additional benefit is that ICU beds could be freed up more quickly. And the less time a patient spends on a ventilator, the better for the patient. This is an exceptionally positive development.’

About Ventinova
Ventinova Medical BV is a Dutch company specialised in innovative ventilation products. Ventinova has been working on the disruptive ventilation method FCV® since 2008, with a prototype marketed in 2010 and a complete concept since 2018. This technology controls both the inspiratory and expiratory phases of mechanical ventilation and this is extremely effective. Ventinova has 21 employers working from its head office in Eindhoven to export its products to 22 countries worldwide. Valued partner Unitron (IJzendijke) will manufacture Evone® and Sonoco Plastics (Berkel en Rodenrijs) will supply the disposables. Also visit www.ventinovamedical.com and www.ventinovamedical.com/covid-19-update/

Cloud service provider Eshgro receives capital injection from Holland Capital to accelerate further growth

Cloud service provider Eshgro receives capital injection from Holland Capital to accelerate further growth

Cloud service provider Eshgro receives capital injection from Holland Capital to accelerate further growth

Cloud service provider Eshgro receives capital injection from Holland Capital to accelerate further growth

Boxmeer / Amsterdam, March 24, 2020 – Investment company Holland Capital has increased its interest in cloud service provider Eshgro. Based in both Boxmeer and Amsterdam, the recent investment enables Eshgro to step up its growth ambitions. The cloud service provider aims to further strengthen its market position by way of organic growth and acquisitions.

Unique solution and rapid growth
With its proprietary software, Eshgro opens up the Microsoft Modern Workplace with industry-specific / business-critical applications. Known as ‘Smarter 365’, this unique solution is rolled out, managed and kept up-to-date for customers in a fully automated fashion. This enables organizations to implement the Modern Workplace within days instead of months and helps realize and manage IT solutions in a faster, easier and more secure way. Savings of up to 50% can be achieved compared to traditional IT service providers. Eshgro’s vision and approach has stuck a chord, as evidenced by the rapid growth of the company, adding over 10 million in recurring revenues driven by its platform.

In times of the Corona virus, the Smarter 365 platform has become even more pertinent. For example, Eshgro offers a free home-office set-up within just 15 minutes, enabling organizations that do not have a home-office solution yet to quickly establish a safe working environment for their employees.

Holland Capital expands interest
Investor Holland Capital, which has been involved with Eshgro as a shareholder since 2015, announces that it has expanded its interest to a majority stake. The main reason for doing so is the wish to continue the rapid growth of Eshgro, both organically and through acquisitions.

Niels van Aalten, partner Holland Capital, says: “The fast-growing recurring turnover, the seamless connection to the Microsoft technology stack and excellent service to direct customers form the main reasons for further support of Eshgro; a logical point in time to increase our stake and achieve further growth.”

Anton Loeffen, CEO Eshgro, adds: “Holland Capital has expertise in positioning fast-growing companies correctly. They therefore make for a valuable partner in our growth process. We owe our current focus to clear sparring sessions with Holland Capital. This is also fully in line with the growth ambitions that Eshgro has clearly set-out before. With the greater financial support from Holland Capital, we can continue to build vigorously. ”